Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

The Terminology Issue for Myeloid-Derived Suppressor Cells

Dmitry I. Gabrilovich, Vincenzo Bronte, Shu-Hsia Chen, Mario P. Colombo, Augusto Ochoa, Suzanne Ostrand-Rosenberg and Hans Schreiber
Dmitry I. Gabrilovich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincenzo Bronte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu-Hsia Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario P. Colombo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Augusto Ochoa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Ostrand-Rosenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Schreiber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-06-3037 Published January 2007
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor:

The recent study by Yang et al. ( 1) described antigen-specific immunosuppression by Gr-1+CD11b+ myeloid cells, which was mediated by the expression of CD80. This report continued a series of recent articles published in Cancer Research, which provided strong evidence in support of a critical role of these cells in tumor progression ( 1– 6). Recent years have witnessed increasing interest in immunosuppressive cells of myeloid origin. During the last 18 months alone, more than 50 articles have appeared in peer-reviewed journals on this subject. Accumulation of these cells has been reported under pathologic conditions, including bacterial and parasitic infections, acute and chronic inflammation, and traumatic stress. However, most of the attention has been focused on the role of these cells in cancer. Immunosuppressive myeloid cells accumulate in large numbers in tumor-bearing mice, in practically all tested experimental models, as well as in patients with breast, lung, prostate, kidney, head and neck, and other types of cancer. These cells are produced in response to a variety of tumor-derived cytokines and are a heterogeneous mixture of myeloid cells at different stages of differentiation. The precise nature of the suppressor cell population (i.e., precursors of granulocytes, macrophages, dendritic cells, or early myeloid progenitors) depends on the tumor and tumor-derived factors of the hosts. Despite this heterogeneity, immunosuppressive myeloid cells share some common characteristics: lack or reduced expression of markers of mature myeloid cells, expression of both Gr-1 and CD11b molecules in mice, inability to differentiate into mature myeloid cells in the presence of tumor-derived factors, high levels of reactive oxygen species, and activation of arginase I and other molecules. Most importantly, these cells possess a high potential to suppress immune responses in vitro and in vivo. Immunosuppressive myeloid cells are now considered by many as a critical mechanism of tumor escape as well as an important immunosuppressive factor for other pathologic conditions.

Because these cells play a key role in regulation of immunity, we feel it necessary to address one issue that causes confusion in this field. These cells lack a clear, unified name. In the literature, these cells have been called “immature myeloid cells” or “myeloid suppressor cells” (MSC). Although both of these names reflect the biology of cells, neither term is entirely accurate. The name “immature myeloid cells” implies that these cells are normal myeloid precursors. However, this may not be the case. Recent studies have shown clear differences in the biology of normal immature myeloid cells and the cells that accumulate in tumor-bearing hosts. In addition, this term does not reflect the most important feature of these cells: their ability to suppress immune responses. The name “MSC” implies that these cells include populations of mature myeloid cells, such as macrophages or dendritic cells, capable of displaying some immunosuppressive features under certain circumstances. However, this name is also not accurate, being too generic and potentially misleading because these cells are not mature myeloid cells. In addition, the abbreviation “MSC” is commonly used for the characterization of mesenchymal stem cells. We believe that the lack of an accurate name for these cells creates confusion and hampers attempts to develop a cohesive picture of the mechanisms of immunosuppression in cancer and other pathologic conditions.

Therefore, we suggest that these cells be called “myeloid-derived suppressor cells”. We believe that this term more closely reflects the origin and function of these cells and hope that it will stimulate further scientific discussions and progress not only in immunology but also in cancer biology where undoubtedly the same or similar cell populations play a major functional role.

  • ©2007 American Association for Cancer Research.

References

  1. ↵
    Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006; 66: 6807–15.
    OpenUrlAbstract/FREE Full Text
  2. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123–31.
    OpenUrlAbstract/FREE Full Text
  3. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044–8.
    OpenUrlAbstract/FREE Full Text
  4. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65: 9525–35.
    OpenUrlAbstract/FREE Full Text
  5. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299–307.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65: 11743–51.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Research: 67 (1)
January 2007
Volume 67, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Terminology Issue for Myeloid-Derived Suppressor Cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Terminology Issue for Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich, Vincenzo Bronte, Shu-Hsia Chen, Mario P. Colombo, Augusto Ochoa, Suzanne Ostrand-Rosenberg and Hans Schreiber
Cancer Res January 1 2007 (67) (1) 425; DOI: 10.1158/0008-5472.CAN-06-3037

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Terminology Issue for Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich, Vincenzo Bronte, Shu-Hsia Chen, Mario P. Colombo, Augusto Ochoa, Suzanne Ostrand-Rosenberg and Hans Schreiber
Cancer Res January 1 2007 (67) (1) 425; DOI: 10.1158/0008-5472.CAN-06-3037
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Quantifying Preexisting Resistant and Persister Populations–Letter
  • Quantifying Preexisting Resistant and Persister Populations–Response
  • Tau Mutations as a Novel Risk Factor for Cancer—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement